17,261 trials
Alcohol Use Disorder · Posttraumatic Stress Disorder (PTSD)
Primary: Change in Percent Drinking Days (PDD) (Visit 8 PDD - Visit 2 PDD) — -37; -9; -14; -15 percentage of drinking days
Solid Tumors · Head and Neck Cancer · Lung Cancer
Primary: Phase 1 : Number of Treatment-Emergent Adverse Events (TEAE) — 6; 3; 4; 4 Participants
Chronic Obstructive Pulmonary Disease
Primary: Change in Sputum Bacteria Biomass — -0.24; -0.14 log10 molecules/uL/mL
Antithrombotic
Primary: The Number of Adverse Events (AEs), Serious AEs (SAEs), AEs Leading to Discontinuation and Death — 4; 4; 3; 2 Participants
Peripheral T-Cell Lymphoma
Primary: Maximum Tolerated Dose — 0; 0; 0; 0 Participants
Nasal Polyposis
Primary: Change in Total Polys Score (TPS) — -0.5; -0.3; -0.2 score on a scale
Leukemia
Primary: Participants With a Response — 49; 19 Participants
Non-Small-Cell Lung Cancer
Primary: Overall Response Rate (ORR) to LDK378 by Investigator Assessment — 25.0 Percentage of participants
Pseudomonas Aeruginosa
Primary: Percentage of Participants With Nosocomial Pneumonia Caused by Pseudomonas Aeruginosa — 18.1; 12.5; 22.4 Percentage of participants — p=0.491
Breast Cancer
Primary: 2-Year Treatment Discontinuation Rate — 31 percentage of participants — p=0.0011
Nocturia
Primary: Change From Baseline in Aggregated Mean Number of Nocturnal Voids During 12 Weeks of Treatment — -1.06; -0.99; -0.89; -0.80 nocturnal voids
Head and Neck Squamous Cell Cancer
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Event (SAEs) — 6; 15; 2; 0 Participants
Patients With Confirmed Malignant Disease to Receive Low Emetogenic Chemotherapy (LEC) or Who Experienced at Least Nausea and Vomiting During Last Cycle of LEC
Primary: Percentage of Participants With Complete Response (CR) During Acute Period (0 to 24 Hours) After Receiving Treatment on Day 1 — 88.2 percentage of participants
Biliary Tract Cancer
Primary: Objective Response Rate (ORR) — 11.5 percentage of participant
Advanced Adult Hepatocellular Carcinoma
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability. — 16; 5 Participants